1) Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res. 2007 ; 111 (Pt 5) : 509-47.
2) Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis : An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 ; 19 : e405-21.
3) Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009 ; 15 (Suppl 5) : 2-9.
4) Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 ; 54 (Suppl 1) : S23-34.
5) Ostrosky-Zeichner L, Smith M, McGinnis MR. Zygomycosis. In : Anaissie EJ, et al. Editors. Clinical Mycology, 2nd ed. Chunrchill Livingstone ; 2009. p.297-307.
6) Davoudi S, Graviss LS, Kontoyiannis DP. Healthcare-associated outbreaks due to Mucorales and other uncommon fungi. Eur J Clin Invest. 2015 ; 45 : 767-73.
7) Uchida T, Okamoto M, Fujikawa K, et al. Gastric mucormycosis complicated by a gastropleural fistula : A case report and review of the literature. Medicine (Baltimore). 2019 ; 98 : e18142.
8) Maravi-Poma E, Rodriguez-Tudela JL, de Jalon JG, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med. 2004 ; 30 : 724-8.
9) Sivagnanam S, Sengupta DJ, Hoogestraat D, et al. Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center. Antimicrob Resist Infect Control. 2017 ; 6 : 123.
10) Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019 ; ciz1008.
11) Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011 ; 91 : 1144-55.
12) Harris B, Geyer AI. Diagnostic evaluation of pulmonary abnormalities in patients with hematologic malignancies and hematopoietic cell transplantation. Clin Chest Med. 2017 ; 38 : 317-31.
13) Zare Mehrjardi M, Kahkouee S, Pourabdollah M. Radio-pathological correlation of organizing pneumonia (OP) : a pictorial review. Br J Radiol. 2017 ; 90 : 20160723.
14) Lee YR, Choi YW, Lee KJ, et al. CT halo sign : the spectrum of pulmonary diseases. Br J Radiol. 2005 ; 78 : 862-5.
15) Godoy MC, Viswanathan C, Marchiori E, et al. The reversed halo sign : update and differential diagnosis. Br J Radiol. 2012 ; 85 : 1226-35.
16) Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis. 2007 ; 44 : 1078-83.
17) Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007 ; 45 : e101-4.
18) Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012 ; 54 (Suppl 1) : S55-60.
19) Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001 ; 19 : 253-9.
20) Klimko N, Khostelidi S, Shadrivova O, et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol. 2019 ; 57 (Suppl 2) : S138-S44.
21) Son HJ, Sung H, Park SY, et al. Diagnostic performance of the (1-3) -β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers. PLoS One. 2017 ; 12 : e0188860.
22) Angebault C, Lanternier F, Dalle F, et al. Prospective evaluation of serum β-Glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis. 2016 ; 3 : ofw128.
23) Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005 ; 49 : 721-7.
24) Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008 ; 47 : 503-9.
25) Kontoyiannis DP, Azie N, Franks B, et al. Prospective antifungal therapy (PATH) alliance (R) : focus on mucormycosis. Mycoses. 2014 ; 57 : 240-6.
26) 河野茂, 泉川公一, 吉田稔, 他. 深在性真菌症の日本人患者を対象としたポサコナゾールの安全性および有効性を検討する無作為化, 実薬対照, 非盲検比較試験. 日本医真菌学会雑誌. 2020 ; 61 : 1-11.
27) Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE) : a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016 ; 387 : 760-9.
28) Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis : a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 ; 16 : 828-37.
29) Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematol. 2017 ; 102 : 433-44.
30) Bays DJ, Thompson GR 3rd. Fungal Infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin North Am. 2019 ; 33 : 545-66.
31) Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008 ; 47 : 364-71.
32) Ota H, Yamamoto H, Kimura M, et al. Successful treatment of pulmonary mucormycosis caused by cunninghamella bertholletiae with high-dose liposomal amphotericin B (10 mg/kg/day) followed by a lobectomy in cord blood transplant recipients. Mycopathologia. 2017 ; 182 : 847-53.
33) West KA, Gea-Banacloche J, Stroncek D, Kadri SS. Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol. 2017 ; 177 : 357-74.
34) Estcourt LJ, Stanworth SJ, Hopewell S, et al. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2016 ; 4 : CD005339.
35) Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019 ; 5 : 26.
36) Lass-Florl C, Cuenca-Estrella M. Changes in the epidemiological landscape of invasive mould infections and disease. J Antimicrob Chemother. 2017 ; 72 (suppl 1) : i5-i11.
37) Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006 : overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010 ; 50 : 1091-100.
38) Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe : analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011 ; 17 : 1859-67.
39) Lamaris GA, Ben-Ami R, Lewis RE, et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole : a study involving fly and murine models of zygomycosis. J Infect Dis. 2009 ; 199 : 1399-406.
40) Lewis RE, Georgiadou SP, Sampsonas F, et al. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses. 2014 ; 57 : 49-55.
41) Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis : a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019 ; 25 : 26-34.
42) Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study : a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012 ; 67 : 715-22.
43) Soman R, Gupta N, Shetty A, et al. Deferasirox in mucormycosis : hopefully, not defeated. J Antimicrob Chemother. 2012 ; 67 : 783-4.
44) Ino K, Nakase K, Nakamura A, et al. Management of pulmonary mucormycosis based on a polymerase chain reaction (PCR) diagnosis in patients with hematologic malignancies : A report of four cases. Intern Med. 2017 ; 56 : 707-11.
45) Shibata W, Niki M, Sato K, et al. Detection of Rhizopus-specific antigen in human and murine serum and bronchoalveolar lavage. Med Mycol. 2020 ; 58 : 958-64.